文献速递妇科

血清人附睾蛋白4与绝经后附件肿块女性卵巢癌的诊断

Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
PubMed 文献 · Am J Obstet Gynecol · 2019-07-24

该队列研究嵌套于英国卵巢癌筛查多中心随机对照试验,评估经阴道超声、CA125和人附睾蛋白4对绝经后附件肿块女性卵巢癌的鉴别诊断效能。纳入1590例附件肿块女性,78例在扫描后1年内诊断为卵巢癌。包含年龄、超声和CA125的模型与再加入人附睾蛋白4的模型相比,曲线下面积(0.893 vs 0.896;P=0.453)和固定特异度90%时的灵敏度(74.4% vs 75.6%;P=0.564)相似。结论提示人附睾蛋白4对CA125和经阴道超声的联合应用附加价值不大。

要点

  • 在绝经后附件肿块女性中,包含CA125和超声的模型诊断卵巢癌的曲线下面积为0.893。
  • 加入人附睾蛋白4后曲线下面积为0.896,与前者相似(P=0.453)。
  • 固定特异度90%时,两模型灵敏度分别为74.4%和75.6%,无显著差异(P=0.564)。

核心结论

  • 人群队列研究提示,在绝经后附件肿块女性的鉴别诊断中,人附睾蛋白4对CA125和经阴道超声的 concurrent 使用附加价值不大。

研究设计与样本

  • 研究为队列研究,嵌套于英国卵巢癌筛查多中心随机对照试验的筛查组,该试验基于英格兰、威尔士和北爱尔兰。
  • 48230名女性随机接受经阴道超声筛查,50078名接受多模式筛查(血清CA125由卵巢癌风险算法解读,二线经阴道超声),均接受首次(患病率)筛查。

主要发现

  • 1590例(158例多模式筛查,1432例超声筛查)附件肿块女性中,78例在扫描后1年内诊断为卵巢癌(48例浸润性上皮性卵巢癌,其中14例I型、34例II型;24例交界性上皮性肿瘤;6例非上皮性肿瘤)。
  • 包含年龄、超声和CA125的模型与再加入人附睾蛋白4的模型相比,曲线下面积(0.893 vs 0.896;P=0.453)和固定特异度90%时的灵敏度(74.4% vs 75.6%;P=0.564)相似。
  • 两模型对浸润性上皮性卵巢癌(灵敏度89.6%)和II型癌(灵敏度>91%)均有高灵敏度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transvaginal ultrasound and serum CA125 are routinely used for differential diagnosis of pelvic adnexal mass. Use of human epididymis 4 was approved in the United States in 2011. However, there is scarcity of studies evaluating the additional value of human epididymis 4. OBJECTIVE: The objective of the study was to evaluate the performance characteristics of transvaginal ultrasound, CA125, and human epididymis 4 for differential diagnosis of ovarian cancer in postmenopausal women with adnexal masses. STUDY DESIGN: This was a cohort study nested within the screen arms of the multicenter randomized controlled trial, United Kingdom Collaborative Trial of Ovarian Cancer Screening, based in England, Wales, and Northern Ireland. In United Kingdom Collaborative Trial of Ovarian Cancer Screening, 48,230 women randomized to transvaginal ultrasound screening and 50,078 to multimodal screening (serum CA125 interpreted by Risk of Ovarian Cancer Algorithm with second line transvaginal ultrasound) underwent the first (prevalence) screen. Women with adnexal lesions and/or persistently elevated risk were clinically assessed and underwent surgery or follow-up for a median of 10.9 years. Banked samples taken within 6 months of transvaginal ultrasound from all clinically assessed women were assayed for human epididymis 4 and CA125. Area under the curve and sensitivity for diagnosing ovarian cancer of multiple penalized logistic regression models incorporating logCA125, log human epididymis 4, age, and simple ultrasound features of the adnexal mass were compared. RESULTS: Of 1590 (158 multimodal, 1432 ultrasound) women with adnexal masses, 78 were diagnosed with ovarian cancer (48 invasive epithelial ovarian, 14 type I, 34 type II; 24 borderline epithelial; 6 nonepithelial) within 1 year of scan. The area under the curve (0.893 vs 0.896; P = .453) and sensitivity (74.4% vs 75.6% ;P = .564) at fixed specificity of 90% of the model incorporating age, ultrasound, and CA125 were similar to that also including human epididymis 4. Both models had high sensitivity for invasive epithelial ovarian (89.6%) and type II (>91%) cancers. CONCLUSION: Our population cohort study suggests that human epididymis 4 adds little value to concurrent use of CA125 and transvaginal ultrasound in the differential diagnosis of adnexal masses in postmenopausal women.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gentry-Maharaj A, Burnell M, Dilley J, et al. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. Am J Obstet Gynecol. 2019. PMID: 31351062. doi:10.1016/j.ajog.2019.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。